<DOC>
	<DOCNO>NCT00000746</DOCNO>
	<brief_summary>Primary : To determine healthy volunteer whether prim vaccinia HIV-1 gp160 envelope gene recombinant vaccine ( HIVAC-1e ) follow boost one two subunit recombinant HIV-1 envelope vaccine ( Env 2-3 gp120 ) provide enhanced immunogenicity compare vaccination gp120 subunit vaccine alone . ( Per 10/01/92 amendment , boost VaxSyn ( gp160 ) eliminate . ) To evaluate immunogenicity one versus two priming dos HIVAC-1e prior boost gp120 . To compare relative immunogenicity three subunit vaccine administer booster . Secondary : To examine safety administer individual subunit vaccine combination HIVAC-1e safety administer gp120 subunit vaccine alone . In previous study candidate HIV vaccine , evidence suggest administration booster vaccination different vaccine preparation may produce good immune response administration HIVAC-1e vaccine alone .</brief_summary>
	<brief_title>A Phase I , Multicenter , Randomized Trial Evaluate Safety Immunogenicity Recombinant Vaccinia-HIV Envelope Vaccine ( HIVAC-1e ) Combination With Panel Subunit Recombinant HIV Envelope Vaccines</brief_title>
	<detailed_description>In previous study candidate HIV vaccine , evidence suggest administration booster vaccination different vaccine preparation may produce good immune response administration HIVAC-1e vaccine alone . Seventy healthy volunteer randomize one four group . Groups A D receive one initial immunization HIVAC-1e follow two boost subunit gp120 Env 2-3 , respectively , month 8 12 . Group B receive two immunization HIVAC-1e month 0 8 follow single boost subunit gp120 month 12 . Group C receive three dos subunit gp120 month 0 , 8 12 . ( Per 10/01/92 amendment , boost VaxSyn ( gp160 ) eliminate . ) Subjects followed 18 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Normal history physical exam . Negative HIV screen ELISA , Western blot , p24 antigen ( PBMC HIV culture HIVspecific PCR substitute Western blot p24 antigen ) . History smallpox vaccination 5 year prior enrollment . Normal urinalysis . Absolute CD4 count = &gt; 500 cells/mm3 . Prior Medication : Required : Vaccinia ( smallpox ) vaccination 5 year prior study enrollment . Identifiable highrisk behavior HIV infection determine screen questionnaire/interview . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Household contact pregnant , &lt; 12 month age , eczema , immunodeficiency disease use immunosuppressive medication . Hepatitis B surface antigenemia . Medical psychiatric condition occupational responsibility preclude compliance . Subjects follow prior condition exclude : History immunodeficiency chronic illness . Eczema within past year . Prior Medication : Excluded : Prior experimental HIV vaccine . Immunoglobulin administration use experimental agent within past 2 month . History immunosuppressive medication . Prior Treatment : Excluded : Blood blood product transfusion within previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>Viral Vaccines</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>